Clinicopathological associations of CD44 mRNA and protein expression in primary breast carcinomas

Berner, HS; Suo, Zhenhe; Risberg, Bjørn; Villman, Kenneth; Karlsson, Mats G.; Jm, Nesland

doi:10.1046/j.1365-2559.2003.01622.x

Cited by 37 publications

(23 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results confirm a recent smaller study of CD44s mRNA expression in invasive breast carcinoma by Berner et al, who reported a significant correlation between CD44s mRNA expression by reverse transcription-PCR analysis and both disease-free and overall survival (17). Our results suggest that CD44s protein expression (or expression of a variant recognized with the anti-CD44s antibody) may be a favorable prognostic factor in node-negative invasive breast carcinoma.…”

Section: Discussionsupporting

confidence: 91%

CD44 Expression Is Associated with Increased Survival in Node-Negative Invasive Breast Carcinoma

Diaz¹,

Zhou²,

Wright³

et al. 2005

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: CD44 is a multifunctional cell surface receptor with many known splice variants, some of which have been reported to play a role in tumor progression. The purpose of this study was to evaluate the prognostic significance of CD44 isoforms in early-stage, lymph node^negative invasive breast carcinoma. Experimental Design: Immunohistochemical staining for CD44 isoforms was done on archival paraffin tissue sections of invasive breast carcinoma from a cohort of lymph node^negative patients who received no adjuvant tamoxifen or chemotherapy and who had a mean clinical follow-up period of 15 years. Immunohistochemical staining was done with antibodies to CD44s, the standard isoform of CD44, and to isoforms containing variant exon 6 (CD44v6); levels of staining were correlated with clinical outcome data.Results: There was a trend towards increased disease-free survival for patients whose tumors had high anti-CD44s positivity (P = 0.05), and a significant association was observed between anti-CD44s positivity and disease-related survival (P = 0.04). Expression of CD44v6 isoforms did not correlate with clinical outcome. Conclusion: CD44 expression, as assessed by immunohistochemical staining with anti-CD44s, may be a favorable prognostic factor in patients with node-negative invasive breast carcinoma.

show abstract

Section: Discussionsupporting

confidence: 91%

CD44 Expression Is Associated with Increased Survival in Node-Negative Invasive Breast Carcinoma

Diaz¹,

Zhou²,

Wright³

et al. 2005

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…These studies are summarized in Table 1, which notes the tumor grade examined (e.g., benign or invasive) and the CD44 isoforms examined when that information was provided by the authors. Of interest, 8 out of 10 studies that focused on mammary tumors classified as either noninvasive or lymph node-negative showed that CD44s (and in some cases CD44v6) expression correlates with favorable prognosis or cellular differentiation, indicative of antitumoral activity (91,(93)(94)(95)(96)(97)(98)(99). The exception to this is a 1995 study by Kaufmann and colleagues (64), who examined tumors graded as node-negative and reported that CD44v6 expression correlates with poor OS.…”

Section: Histopathological Cd44 In Human Cancermentioning

confidence: 99%

Understanding the Dual Nature of CD44 in Breast Cancer Progression

Louderbough

Schroeder

2011

Molecular Cancer Research

241

181

View full text Add to dashboard Cite

CD44 has been the subject of extensive research for more than 3 decades because of its role in breast cancer, in addition to many physiological processes, but interestingly, conflicting data implicate CD44 in both tumor suppression and tumor promotion. CD44 has been shown to promote protumorigenic signaling and advance the metastatic cascade. On the other hand, CD44 has been shown to suppress growth and metastasis. Histopathological studies of human breast cancer have correlated CD44 expression with both favorable and unfavorable clinical outcomes. In recent years, CD44 has garnered significant attention because of its utility as a stem cell marker and has surfaced as a potential therapeutic target, necessitating a greater understanding of CD44 in breast cancer. In this review, we attempt to unify the literature implicating CD44 in both tumor promotion and suppression, and explain its dualistic nature. Mol Cancer Res; 9(12); 1573-86. Ó2011 AACR.

show abstract

“…Unlike hyaluronan, increased expression of CD44s correlates with overall patient survival (40,41). Furthermore, CD44s is expressed at a higher level in tubular carcinoma, a subtype of breast ductal carcinoma that rarely metastasize, compared with invasive micropapillary carcinoma, a variant of breast ductal carcinoma with a high metastatic potential and poor clinical outcome (42).…”

Section: Roles Of Hyaluronan and Cd44 In Breast Cancermentioning

confidence: 99%

Heparanase, Hyaluronan, and CD44 in Cancers: A Breast Carcinoma Perspective

2006

View full text Add to dashboard Cite

Glycosaminoglycans are major constituents of the cancer cell surface and the tumor stroma. The heparan sulfate degrading enzyme heparanase, hyaluronan, and its receptor CD44 are up-regulated in breast cancer, generating a microenvironment that promotes tumor progression and metastasis. Recent experimental and clinical evidence shows that heparanase, hyaluronan, and CD44 regulate cancer cell proliferation, migration, and invasion, as well as tumor-associated angiogenesis and are correlated with patient survival. These findings suggest that they may be used as prognostic factors and targets for breast cancer treatment. (Cancer Res 2006; 66(21): 10233-7)

show abstract

Clinicopathological associations of CD44 mRNA and protein expression in primary breast carcinomas

Cited by 37 publications

References 59 publications

CD44 Expression Is Associated with Increased Survival in Node-Negative Invasive Breast Carcinoma

CD44 Expression Is Associated with Increased Survival in Node-Negative Invasive Breast Carcinoma

Understanding the Dual Nature of CD44 in Breast Cancer Progression

Heparanase, Hyaluronan, and CD44 in Cancers: A Breast Carcinoma Perspective

Contact Info

Product

Resources

About